Arrowhead appoints Dr. Matt Cohen to board of directors

ARROWHEAD PHARMACEUTICALS, INC.

Appointed Dr. Matt Cohen, M.D., M.B.A., as director effective June 12, 2026.
Cohen is Managing Director at Vida Ventures; previously lead healthcare investor at JPMorgan for ~20 years.
Received standard non-employee director compensation plus sign-on RSU grant of $887,000 vesting over three years.
No family relationships or arrangements with any other director or officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Matt Cohen

Director

ARWR · ARROWHEAD PHARMACEUTICALS, INC.

Effective: 2026-06-12
Filed: June 16, 2026, 4:02 PM ET

On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Matt Cohen was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.

View on SEC.gov

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0000879407-26-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.